The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

It has been eye-opening to understand the link between my ADHD diagnosis and my decision to pursue self-employment.

The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

Attention-Deficit Hyperactivity Disorder, or ADHD, affects tens of millions of people in the U.S.About one in nine children ...

For years, people thought that attention deficit hyperactivity disorder (ADHD) was a problem that only kids had. It was ...

Many adults assume their challenges reflect personal shortcomings rather than a neurological difference”— Dr. Stanford ...

When the NHS recognised ADHD in adults in 2008, never in my wildest hypochondriacal dreams did I imagine it applied to me. I ...

Adults with ADHD may die up to 11 years younger, new research finds - Around 2.6 million adults in the UK have ADHD, but ...